Short-term adjunctive use of a liposomal tear substitute after repeated intravitreal therapy: a randomized pilot study.
Int OphthalmolSep 16, 2026 (epub)
Carlo Cagini, Marco Messina, Tito Fiore et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized pilot study evaluated the effectiveness of a liposomal tear substitute in reducing dry eye symptoms in patients over 50 undergoing repeated intravitreal therapy. Among 90 participants, those receiving the adjunctive eye drops showed significant improvements in DEQ-5 scores (9.28 ± 3.24 to 8.00 ± 3.64, p < 0.0001) compared to standard therapy alone.
Key findings
- Group 2 showed a significant reduction in DEQ-5 scores from 9.28 ± 3.24 to 8.00 ± 3.64 (p < 0.0001).
- OSDI scores improved significantly in Group 2 (p < 0.0001), while Group 1 showed no relevant change (p = 0.497).
- Group 2 had notable enhancements in TBUT and Schirmer tests (p < 0.0001).
- Group 1 experienced a significant decrease in TBUT values (p = 0.026).
Why it matters
The findings highlight the potential for adjunctive therapies to alleviate ocular surface issues in patients receiving chronic intravitreal treatments, which is crucial for maintaining patient comfort and adherence to therapy.